©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Nov 24, 2015; 4(3): 104-107
Published online Nov 24, 2015. doi: 10.5410/wjcu.v4.i3.104
Published online Nov 24, 2015. doi: 10.5410/wjcu.v4.i3.104
Sweet side of bladder cancer
Paula A Videira, UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal
Author contributions: Videira PA wrote and revised the manuscript.
Conflict-of-interest statement: No conflicts of interest.
Correspondence to: Paula A Videira, Professor, UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campo dos Mártires da Pátria no. 130, 2829-516 Caparica, Portugal. p.videira@fct.unl.pt
Telephone: +351-9-68169892 Fax: +351-2-12954461
Received: May 23, 2015
Peer-review started: May 23, 2015
First decision: September 18, 2015
Revised: September 21, 2015
Accepted: November 13, 2015
Article in press: November 17, 2015
Published online: November 24, 2015
Processing time: 191 Days and 10.9 Hours
Peer-review started: May 23, 2015
First decision: September 18, 2015
Revised: September 21, 2015
Accepted: November 13, 2015
Article in press: November 17, 2015
Published online: November 24, 2015
Processing time: 191 Days and 10.9 Hours
Core Tip
Core tip: The deranged expression of glycans in bladder cancer has been reported, but somehow disregarded. Glycans, such as the sialyl Tn, show a very tumor specific pattern and have been suggested as diagnostic and prognostic biomarkers of bladder cancer, and associated with disease progression and patient’s response to treatment. Understandings about the role of glycans in bladder cancer is still limited, but, it is now assumed that this understanding urges and it will fuel the development of novel strategies of diagnostic and therapy.